Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis Partnering With Yale on Assays for Assessing Immune Response to COVID-19

NEW YORK –Single-cell proteomics firm IsoPlexis said Thursday that it is partnering with Yale University to develop assays for COVID-19 using the company's IsoLight system.

According to the company, the partners aim to identify markers of patient immune response to the virus that could be used to inform development of therapies and vaccines for the disease.

"We are looking forward to utilizing the IsoLight's unique ability to functionally phenotype each immune cell in patients with COVID-19 for more than 30 effector functions simultaneously, providing a comprehensive picture and the direct evidence of antiviral immune activation or immune-mediated hyperinflammatory pathology that is impossible with other technologies," Yale Professor Rong Fan, the lead investigator of the study, said in a statement.

Fan is a co-founder of IsoPlexis as well as the chair of its scientific advisory board.

"This work will provide critical functional insights into the mechanisms of various immune responses to COVID," said IsoPlexis CEO Sean Mackay. "Through the identification of novel rapid circulating markers, we hope to help accelerate the development of critical therapeutics and vaccines."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.